Statins: lowering LDL cholesterol, myths and side effects

The classic case: a 58-year-old patient, LDL 165 mg/dL, hypertensive, a 20 pack-year smoker. The doctor prescribes atorvastatin 20 mg. Three months later he comes to the pharmacy and says: "My neighbour told me statins cause cancer and dementia, I read on Facebook that they destroy my liver, I want to stop them." Statins are the best-studied group of lipid-lowering medicines — and the most abandoned for reasons of myth.

How statins work

Statins inhibit HMG-CoA reductase, the rate-limiting enzyme in hepatic cholesterol synthesis. The result: the liver produces less endogenous cholesterol, displays more LDL receptors on its surface and "vacuums" LDL out of the blood. The typical effect at 4-6 weeks: LDL falls by 25-55% depending on the statin and the dose.

There are additional ("pleiotropic") benefits: stabilisation of the atherosclerotic plaque, an anti-inflammatory effect, a reduction in thrombosis risk. The large studies (4S, HPS, JUPITER, IMPROVE-IT) showed significant reductions in myocardial infarction, ischaemic stroke and mortality in patients with high cardiovascular risk or with established disease.

The statins available in Romania

All have multiple generics reimbursed by CNAS, listed in CANAMED. Usual reimbursement 50% or 90% on List B/C2 depending on the indication and prescriber (cardiologist, diabetologist, nephrologist).

Who should take a statin

The ESC/EAS 2019 guidelines, also adopted by the Romanian Society of Cardiology, identify four main categories:

• Secondary prevention — a patient with established cardiovascular disease (MI, stroke, bypass, stent, arterial disease). LDL target <55 mg/dL, a reduction >50% from baseline.
• Very high risk — diabetes with target-organ damage, severe chronic kidney disease, SCORE2 ≥10%. LDL target <55 mg/dL.
• High risk — diabetes without damage, severe hypertension, familial hypercholesterolaemia. LDL target <70 mg/dL.
• Moderate risk — adults 40-69 with multiple factors. An individual decision, LDL target <100 mg/dL.

Myths vs. reality

"Statins cause cancer"

Large meta-analyses (Cholesterol Treatment Trialists, Lancet) of >170,000 patients found no increase in cancer risk. Observational studies even suggested protection for some types (colon, prostate), but there is no definitive evidence.

"Statins destroy the liver"

An ALT/AST rise >3x normal occurs in <1% of patients and is reversible on stopping. The current recommendation is a transaminase test at initiation; routine monitoring is no longer required in the absence of symptoms or risk factors.

"Statins cause dementia"

In 2012 the FDA noted reports of reversible cognitive disturbances, but the large randomised trials (HPS, PROSPER, Cochrane meta-analyses) did not confirm a dementia signal. On the contrary, the data suggest modest protection.

Real side effects worth the discussion

• Myalgia — 5-10% of patients report muscle pain. True statin-associated myalgia occurs in ~1-3%; the rest is nocebo (blinded "n-of-1" studies).
• Rhabdomyolysis — extremely rare (~1 case per 10,000 patient-years). Increased risk at high doses, simvastatin + macrolides, ciclosporin, fibrates.
• New-onset diabetes — an extra absolute risk of ~0.1-0.2%/year in prediabetic patients; the cardiovascular benefit clearly outweighs it.
• Major interactions: simvastatin with macrolides, antifungal azoles, amiodarone, verapamil/diltiazem, ciclosporin. When in doubt, ask the pharmacist.

The practical strategy: adherence, switching, alternatives

Real adherence to statins in Romania is modest — many prescriptions are not refilled after 6-12 months. Strategies that help:

• Education: explaining the LDL target, not just "take it".
• Switching the statin if real myalgia appears: rosuvastatin → atorvastatin or pravastatin. Pravastatin and fluvastatin are the best tolerated in the "intolerant" patient.
• Alternative doses: rosuvastatin 5 mg 2-3x/week may be enough in a sensitive patient.
• Adding ezetimibe (Ezetrol, Ezatadyn): an extra 15-25% reduction.
• In secondary prevention with an LDL impossible to reach: PCSK9 (alirocumab/evolocumab) — cardiologist Rx, CNAS-reimbursed under strict conditions.

Frequently asked questions

Do I have to take the statin in the evening?

Atorvastatin and rosuvastatin have a long half-life — the time matters little. Simvastatin and fluvastatin — preferably in the evening.

Can I stop the statin once LDL has reached target?

No. The benefit comes from maintaining the reduction. On stopping, LDL returns to the pre-treatment level within 4-8 weeks.

Statin + grapefruit?

Atorvastatin and simvastatin interact — avoid daily grapefruit. Rosuvastatin and pravastatin are not affected.

Do coenzyme Q10 supplements help with myalgia?

A plausible mechanism (statins lower CoQ10), modest clinical evidence, but relatively safe. It does not replace switching the statin.

What is red yeast rice?

It contains natural lovastatin. Real efficacy, but imprecise dosing and irregular quality. Do not use it instead of a prescribed statin.

Do statins cause fatigue?

The reported asthenia is often real, but blinded controlled comparisons show that a significant part is nocebo.

The cardiovascular risk calculation — how it is done concretely

SCORE2 (for 40-69 years) and SCORE2-OP (over 70 years) are the tools recommended by the ESC for estimating the 10-year risk of a fatal and non-fatal cardiovascular event. The input variables: age, sex, smoker/ non-smoker, systolic blood pressure, non-HDL cholesterol. Romania is classified as a country with very high risk, which means the same combination of factors gives a higher absolute risk than in low-risk countries.

Pragmatically: a 55-year-old man who smokes, with BP 150/95 mmHg and total cholesterol 250 mg/dL already has a risk >10% — the high-risk category; LDL target <70 mg/dL, an indication for a statin even without a history. Mobile apps (the ESC HeartScore) or online calculators ease the doctor-patient discussion.

LDL, non-HDL, ApoB — what really matters

For years, LDL-C was the single target. Today the guidelines place growing emphasis on non-HDL (total cholesterol minus HDL) and apolipoprotein B, which reflect the total number of atherogenic particles — relevant especially in patients with raised triglycerides, diabetics, metabolic syndrome. The non-HDL targets are 30 mg/dL above the LDL targets for the same risk category.

Diet and exercise — how much do they lower cholesterol?

• The Mediterranean diet (PREDIMED) — an LDL reduction of 5-10%, but a CV risk reduction greater than is explained by lipids alone.
• Reducing saturated fat to <7% of calories — lowers LDL by 5-10%.
• Soluble fibre (oats, legumes, psyllium) — 5-10 g/day lower LDL by ~5%.
• Plant sterols/stanols (Becel pro-activ) — 2 g/day lower LDL by ~10%.
• Aerobic exercise — modest on LDL, large on HDL and triglycerides; reduces overall CV risk.
• 5-10% weight loss — improves all the lipid components.

Conclusion: diet and movement can cover roughly the reduction offered by a low dose of statin. In patients with moderate risk and mild hyperlipidaemia — first line. In high or very high risk — necessary but not sufficient.

Modern combinations

• Statin + ezetimibe (Atozet, Inegy) — a combo available in RO; LDL falls an extra 15-25% versus statin monotherapy. It reduces CV risk (the IMPROVE-IT trial).
• Statin + bempedoic acid (Nilemdo) — an alternative in the statin-intolerant patient; recently available, reimbursed in a limited way.
• Statin + PCSK9 (alirocumab Praluent, evolocumab Repatha) — an additional LDL reduction of up to 60%. A restricted indication in RO to secondary prevention with LDL >100 mg/dL under the maximum tolerated statin + ezetimibe, cardiologist prescription.
• Inclisiran (Leqvio) — an anti-PCSK9 siRNA, injections every 6 months — available in the EU, still being implemented in RO.

Sources

• ESC/EAS 2019 — Guidelines for the Management of Dyslipidaemias
• ESC/ESH 2024 — cardiovascular prevention update
• Cholesterol Treatment Trialists' (CTT) Collaboration — meta-analyses
• SCORE2 / SCORE2-OP — the European CV risk algorithm
• ANMDMR — SmPCs for atorvastatin, rosuvastatin, simvastatin
• BNF — lipid-modifying drugs
• EMA — statin class review
• IMPROVE-IT trial — ezetimibe + simvastatin
• CNAS — reimbursement lists B and C; CANAMED

Curat de echipa HartaFarmacii — informații sintetizate din surse publice (ANMDMR, EMA, BNF, CNAS), revizuit periodic. Acest material nu înlocuiește consultul medical.